Rigel Pharmaceuticals Inc (RIGL)
- Sector
- Biotechnology
- Last price
- $42.92
- As of
Kresmion compiles this page from RIGL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
RIGEL PHARMACEUTICALS INC (RIGL): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-05.
See the full RIGL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RIGL on one page. Preview it with sample data, then open it live with a free account.
Preview the RIGL dossierActive events for RIGL
- mediumEarnings below estimates
Q3-2026: Missed consensus by 23.8%, EPS $0.65 vs $0.8534 estimate
- mediumEarnings above estimates
Q2-2026: Beat consensus by 39.2%, EPS $0.88 vs $0.6324 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +69% to RIGL (2026Q2)
- high13F: large increase
CITADEL ADVISORS LLC added +144% to RIGL (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 65% of RIGL (2026Q2)
FREE, NO ACCOUNT
Every event on RIGL, as it fires
You are seeing 5 of 11 events recorded on RIGL since 2026-05-26.
The five above landed across 3 days. The other 6 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
RIGL positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 766559702 · 2026Q3 | $3.5M | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RIGL
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
More data on RIGL
RIGL against its peers
RIGL's operating margin of 42.6% ranks in the 88th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RIGL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 294M USD | 107M USD | 71 | 11 |
| Gross margin | 93.3% | n/a | n/a | 2 |
| Operating margin | 42.6% | -43.8% | 88 | 11 |
| Net margin | 124.7% | -31.2% | 88 | 11 |
| Return on equity | 93.8% | -38.7% | 97 | 16 |
| P / E | 2.2x | n/a | n/a | 1 |
| 1 year | 4.9% | 4.1% | 50 | 16 |
Peers (18): SNDX, MGTX, IRWD, CRVS, TBPH, GLUE, PHAR, ARDX, ORIC, LXRX, PRME, SLDB, AURA, JANX, SGMT, XOMA.D, IMTX, SVRA. Left out: LTGO (no annual filing), BBTX (no annual filing), IVA (period gap), AKTS (no annual filing), OBX (no annual filing), CTY (no annual filing), ODTX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RIGL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in RIGL on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on RIGL in the last 180 days.
Upstream: SEC EDGAR filings for RIGL
Kresmion, "RIGEL PHARMACEUTICALS INC (RIGL) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/RIGL. Upstream data: SEC EDGAR filings for RIGL.
Link to this data (HTML):
<a href="https://kresmion.com/research/RIGL">RIGEL PHARMACEUTICALS INC (RIGL) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow RIGL on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to RIGL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.